PKC-beta II expression has prognostic impact in nodal diffuse large B-cell lymphoma

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Protein kinase C-beta II (PKC-beta II) is a potential prognostic marker in diffuse large B-cell lymphoma (DLBCL).
• Previous studies suggest a link between gene expression, immunohistochemistry, and DLBCL prognosis.

Purpose of the Study:

• To investigate the prognostic significance of PKC-beta II expression in nodal DLBCL patients.
• To determine if PKC-beta II is an independent prognostic factor in DLBCL, particularly within the low-risk International Prognostic Index (IPI) group.

Main Methods:

• Immunohistochemistry was used to detect PKC-beta II protein expression in 125 nodal DLBCL patient tissue samples.
• Patients were stratified by the International Prognostic Index (IPI) risk group.
• Statistical analyses, including Cox regression, were performed to assess survival outcomes (Overall Survival and Event-Free Survival).

Main Results:

• PKC-beta II positivity was observed in 38% of patients.
• PKC-beta II expression was associated with worse 5-year Event-Free Survival (EFS) (36% vs 49%, P=0.054).
• In low-risk IPI patients, PKC-beta II expression correlated with significantly worse 5-year Overall Survival (OS) (60% vs 76%, P=0.033) and EFS (48% vs 66%, P=0.014).
• Cox regression identified both PKC-beta II expression and IPI as independent poor prognostic factors for EFS and OS.

Conclusions:

• PKC-beta II expression is an independent poor prognostic factor in nodal DLBCL.
• The combination of PKC-beta II expression and IPI status provides valuable prognostic information, especially for low-risk patients.
• These findings highlight PKC-beta II as a potential therapeutic target in DLBCL management.